



Recent Progress on Vaccine Development against Infectious Diseases

Guest Editors:

Dr. Xiaohua Ye

Institute of Molecular Medicine
McGovern Medical School, The
University of Texas Health
Science Center at Houston,
Houston, TX 77030, USA

Dr. Zhiqiang Ku

Institute of Molecular Medicine
McGovern Medical School, The
University of Texas Health
Science Center at Houston,
Houston, TX 77030, USA

Dr. Srinivasa Reddy Bonam

Department of Microbiology &
Immunology, University of Texas
Medical Branch, Galveston, TX
77550, USA

Deadline for manuscript
submissions:

closed (15 June 2023)

Message from the Guest Editors

Vaccination is one of the most effective measures to prevent the spreading of infectious diseases, including the ongoing catastrophic coronavirus disease 2019 (COVID-19) pandemic. Thanks to the worldwide resource and endeavor, two mRNA-based vaccines, which are the first of the class, are available within one year since the discovery of the causative agent. However, the field still faces big challenges ahead. This special issue focuses on the most recent progress and current vaccine development in the vaccine. We sincerely invite you to contribute an original research article, review, or perspective on the latest researches to highlight, (i) novel experimental vaccine candidates, (ii) novel adjuvants and delivery vehicles, (iii) immune responses elicited by a novel vaccine, (iv) concerns and optimizations of vaccine strategies. This special issue emphasizes on major infectious diseases caused by viruses, but related topics on other human pathogens, such as bacteria, fungi, and parasites, are also welcomed.





an Open Access Journal by MDPI

Editor-in-Chief

Prof. Dr. Ralph A. Tripp

Department of Infectious
Diseases, College of Veterinary
Medicine, University of Georgia,
Athens, GA 30602-7387, USA

Message from the Editor-in-Chief

Vaccines (ISSN 2076-393X) has had a 6-year history of publishing peer-reviewed state of the art research that advances the knowledge of immunology in human disease protection. Immunotherapeutics, prophylactic vaccines, immunomodulators, adjuvants and the global differences in regulatory affairs are some of the highlights of the research published that have shaped global health. Our open access policy allows all researchers and interested parties to immediately scrutinize the rigorous evidence our publications have to offer. We are proud to present the work and perspectives of many to contribute to future decisions concerning human health.

Author Benefits

Open Access:— free for readers, with [article processing charges \(APC\)](#) paid by authors or their institutions.

High Visibility: indexed within [Scopus](#), [SCIE \(Web of Science\)](#), [PubMed](#), [PMC](#), [Embase](#), [CAPus / SciFinder](#), and [other databases](#).

Journal Rank: JCR - Q1 (*Immunology*) / CiteScore - Q1 (*Pharmacology (medical)*)

Contact Us

Vaccines
MDPI, St. Alban-Anlage 66
4052 Basel, Switzerland

Tel: +41 61 683 77 34
www.mdpi.com

mdpi.com/journal/vaccines
vaccines@mdpi.com